Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane.

PMID: 31387460
Journal: PERFUSION-UK
Year: 2020
Reference: Perfusion. 2020 Apr;35(3):267-270. doi: 10.1177/0267659119864813. Epub 2019 Aug 7.
Impact factor:
Publication type: Paper in international publication
Authors: Argudo, Eduard; Ferrer, Ricard; Grau, Santiago; Lopez-Meseguer, Manuel; Los-Arcos, Ibai; Luque, Sonia; Nuvials, Xavier; Riera, Jordi; Sandiumenge, Alberto et al.
DOI: 10.1177/0267659119864813

Effet de l'Evobrutinib, inhibiteur de la tyrosine kinase de Bruton, sur les taux de cellules immunitaires et d'immunoglobulines sur 48 semaines dans le cadre d'une etude de phase 2 sur la sclerose en plaques recurrente.

PMID: 32906528
Journal: REVUE NEUROLOGIQUE
Year: 2020
Reference: Rev Neurol (Paris). 2020 Sep;176S:S81. doi: 10.1016/j.neurol.2020.01.242.
Impact factor: 1.911
Publication type: Paper in international publication
Authors: Montalban, Xavier, Shaw, Jamie, Martin, Emily, Grenningloh, Roland, Weber, Martin S, Vermersch, Patrick, Dangond, Fernando et al.
DOI: 10.1016/j.neurol.2020.01.242

Effet de l'Evobrutinib, inhibiteur de la tyrosine kinase de Bruton, sur les taux de cellules immunitaires et d'immunoglobulines sur 48 semaines dans le cadre d'une etude de phase 2 sur la sclerose en plaques recurrente.

PMID: 32906528
Journal: REVUE NEUROLOGIQUE
Year: 2020
Reference: Rev Neurol (Paris). 2020 Sep;176S:S81. doi: 10.1016/j.neurol.2020.01.242.
Impact factor:
Publication type: Paper in international publication
Authors: Dangond, Fernando; Grenningloh, Roland; Martin, Emily; Montalban, Xavier; Shaw, Jamie; Vermersch, Patrick; Weber, Martin S et al.
DOI: 10.1016/j.neurol.2020.01.242

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

PMID: 31806627
Journal: Cancer Discovery
Year: 2020
Reference: Cancer Discov. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. Epub 2019 Dec 5.
Impact factor: 29.497
Publication type: Paper in international publication
Authors: Smyth, Lillian M, Piha-Paul, Sarina A, Won, Helen H, Schram, Alison M, Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I, Juric, Dejan, Scaltriti, Maurizio et al.
DOI: 10.1158/2159-8290.CD-19-0966

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

PMID: 31806627
Journal: Cancer Discovery
Year: 2020
Reference: Cancer Discov. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. Epub 2019 Dec 5.
Impact factor:
Publication type: Paper in international publication
Authors: Arnedos, Monica; Arteaga, Carlos L; Baselga, Jose; Bidard, Francois-Clement; Boni, Valentina; Brufksy, Adam M; Bryce, Richard; Cai, Yanyan; Cervantes, Andres; Chandarlapaty, Sarat et al.
DOI: 10.1158/2159-8290.CD-19-0966

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

PMID: 32293523
Journal: Trials
Year: 2020
Reference: Trials. 2020 Apr 15;21(1):328. doi: 10.1186/s13063-020-4226-2.
Impact factor: 1.883
Publication type: Paper in international publication
Authors: Molina-Morant, D, Fernandez, M L, Bosch-Nicolau, P, Sulleiro, E, Bangher, M, Salvador, F, Sanchez-Montalva, A, Ribeiro, A L P, de Paula, A M B, Eloi, S et al.
DOI: 10.1186/s13063-020-4226-2

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

PMID: 32293523
Journal: Trials
Year: 2020
Reference: Trials. 2020 Apr 15;21(1):328. doi: 10.1186/s13063-020-4226-2.
Impact factor:
Publication type: Paper in international publication
Authors: Bangher, M; Bosch-Nicolau, P; Correa-Oliveira, R; de Paula, A M B; Eloi, S; Fernandez, M L; Molina, I; Molina-Morant, D; Ribeiro, A L P; Salvador, F et al.
DOI: 10.1186/s13063-020-4226-2

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.

PMID: 31259813
Journal: RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
Year: 2020
Reference: Retina. 2020 Jul;40(7):1234-1244. doi: 10.1097/IAE.0000000000002582.
Impact factor: 3.649
Publication type: Paper in international publication
Authors: Cervera, Enrique, Vilimelis, Jaume Crespi, Escobar, Jose Juan, Escobar, Antonio Gomez, Zapata, Miguel Angel, Arias, Luis et al.
DOI: 10.1097/IAE.0000000000002582

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.

PMID: 31259813
Journal: RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
Year: 2020
Reference: Retina. 2020 Jul;40(7):1234-1244. doi: 10.1097/IAE.0000000000002582.
Impact factor:
Publication type: Paper in international publication
Authors: Arias, Luis; Cervera, Enrique; Escobar, Antonio Gomez; Escobar, Jose Juan; Vilimelis, Jaume Crespi; Zapata, Miguel Angel et al.
DOI: 10.1097/IAE.0000000000002582

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

PMID: 31865857
Journal: LUPUS
Year: 2020
Reference: Lupus. 2020 Feb;29(2):118-125. doi: 10.1177/0961203319896018. Epub 2019 Dec 22.
Impact factor: 2.251
Publication type: Paper in international publication
Authors: Segarra, A, Arredondo, K V, Jaramillo, J, Jatem, E, Salcedo, M T, Agraz, I, Ramos, N, Carnicer, C, Valtierra, N, Ostos, E et al.
DOI: 10.1177/0961203319896018

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

PMID: 31865857
Journal: LUPUS
Year: 2020
Reference: Lupus. 2020 Feb;29(2):118-125. doi: 10.1177/0961203319896018. Epub 2019 Dec 22.
Impact factor:
Publication type: Paper in international publication
Authors: Agraz, I; Arredondo, K V; Carnicer, C; Jaramillo, J; Jatem, E; Ostos, E; Ramos, N; Salcedo, M T; Segarra, A; Valtierra, N et al.
DOI: 10.1177/0961203319896018

Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.

PMID: 33413989
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2020
Reference: Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec 9. pii: S0213-005X(20)30413-4. doi: 10.1016/j.eimc.2020.10.023.
Impact factor: 1.654
Publication type: Paper in national publication
Authors: Alonso, Manuel, Espuga, Meritxell, Esperalba, Juliana, Gorgas, M feminine Queralt, Almirante, Benito, Ribera, Esteban, Andres, Cristina, Vidal, Xavier, Anton, Andres, Agusti, Antonia et al.
DOI: 10.1016/j.eimc.2020.10.023

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

PMID: 32880601
Journal: JAMA Oncology
Year: 2020
Reference: JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370.
Impact factor: 24.799
Publication type: Paper in international publication
Authors: Van Cutsem, Eric, Shitara, Kohei, Tabernero, Josep, Shah, Sukrut, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun et al.
DOI: 10.1001/jamaoncol.2020.3370

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

PMID: 32880601
Journal: JAMA Oncology
Year: 2020
Reference: JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370.
Impact factor:
Publication type: Paper in international publication
Authors: Alsina, Maria; Bang, Yung-Jue; Benson, Al; Braghiroli, Maria Ignez; Caglevic, Christian; Castro, Hugo Raul; Chao, Joseph; Chung, Hyun Cheol; Enzinger, Peter; Fuchs, Charles et al.
DOI: 10.1001/jamaoncol.2020.3370

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).

PMID: 32674461
Journal: Cancers
Year: 2020
Reference: Cancers (Basel). 2020 Jul 14;12(7). pii: cancers12071900. doi: 10.3390/cancers12071900.
Impact factor: 6.126
Publication type: Paper in international publication
Authors: Arenas, Juan I, Banales, Jesus M, Perugorria, Maria J, Minguez, Beatriz, Riano, Ioana, Martin, Leticia, Varela, Maria, Serrano, Trinidad, Nunez, Oscar, Rodrigues, Pedro M et al.
DOI: 10.3390/cancers12071900

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).

PMID: 32674461
Journal: Cancers
Year: 2020
Reference: Cancers (Basel). 2020 Jul 14;12(7). pii: cancers12071900. doi: 10.3390/cancers12071900.
Impact factor:
Publication type: Paper in international publication
Authors: Arenas, Juan I; Banales, Jesus M; Martin, Leticia; Minguez, Beatriz; Nunez, Oscar; Perugorria, Maria J; Riano, Ioana; Rodrigues, Pedro M; Serrano, Trinidad; Varela, Maria et al.
DOI: 10.3390/cancers12071900

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.

PMID: 31600365
Journal: JAMA Oncology
Year: 2020
Reference: JAMA Oncology. 2020 Jan 9;6(1):e193531. doi: 10.1001/jamaoncol.2019.3531.
Impact factor: 24.799
Publication type: Paper in international publication
Authors: Prokharau, Aliaksandr, Arkenau, Hendrik-Tobias, Ghidini, Michele, Fujitani, Kazumasa, Van Cutsem, Eric, Thuss-Patience, Peter, Beretta, Giordano D, Mansoor, Wasat, Zhavrid, Edvard, Alsina, Maria et al.
DOI: 10.1001/jamaoncol.2019.3531

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.

PMID: 31600365
Journal: JAMA Oncology
Year: 2020
Reference: JAMA Oncology. 2020 Jan 9;6(1):e193531. doi: 10.1001/jamaoncol.2019.3531.
Impact factor:
Publication type: Paper in international publication
Authors: Alsina, Maria; Arkenau, Hendrik-Tobias; Beretta, Giordano D; Catenacci, Daniel; Doi, Toshihiko; Fujitani, Kazumasa; George, Ben; Ghidini, Michele; Ilson, David H; Makris, Lukas et al.
DOI: 10.1001/jamaoncol.2019.3531

Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.

PMID: 33096456
Journal: SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
Year: 2020
Reference: Seizure. 2020 Dec;83:48-56. doi: 10.1016/j.seizure.2020.09.026. Epub 2020 Oct 7.
Impact factor: 2.522
Publication type: Paper in international publication
Authors: Davila-Gonzalez, Pablo, Santamarina, Estevo, Bertol, Vicente, Garayoa, Vanesa, Garcia-Gomara, Maria Jose, Garamendi-Ruiz, Inigo, Giner, Pau, Aranzabal, Ines, Piera, Anna, Arcos, Carolina et al.
DOI: 10.1016/j.seizure.2020.09.026

Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.

PMID: 33096456
Journal: SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
Year: 2020
Reference: Seizure. 2020 Dec;83:48-56. doi: 10.1016/j.seizure.2020.09.026. Epub 2020 Oct 7.
Impact factor:
Publication type: Paper in international publication
Authors: Aranzabal, Ines; Arcos, Carolina; Bertol, Vicente; Bonet, Macarena; Casadevall, Teresa; Davila-Gonzalez, Pablo; de Tienda, Alejandro Ponz; Esteve, Patricia; Garamendi-Ruiz, Inigo; Garayoa, Vanesa et al.
DOI: 10.1016/j.seizure.2020.09.026

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.

PMID: 32131866
Journal: CRITICAL CARE
Year: 2020
Reference: Crit Care. 2020 Mar 4;24(1):74. doi: 10.1186/s13054-020-2792-z.
Impact factor: 6.407
Publication type: Paper in international publication
Authors: Schneider, Hauke, Kanesa-Thasan, Niranjan, Eder-Lingelbach, Susanne, Klingler, Anton, Dubischar, Katrin, Wressnigg, Nina, Rello, Jordi, Sramek, Vladimir, Hejja, Maria, Schaaf, Bernhard et al.
DOI: 10.1186/s13054-020-2792-z

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.

PMID: 32131866
Journal: CRITICAL CARE
Year: 2020
Reference: Crit Care. 2020 Mar 4;24(1):74. doi: 10.1186/s13054-020-2792-z.
Impact factor:
Publication type: Paper in international publication
Authors: Adlbrecht, Christopher; Creteur, Jacques; Depuydt, Pieter; Dubischar, Katrin; Eder-Lingelbach, Susanne; Eller, Philipp; Hejja, Maria; Kanesa-Thasan, Niranjan; Klingler, Anton; Laenen, Margot Vander et al.
DOI: 10.1186/s13054-020-2792-z

Efficacy of a Multicomponent Intervention for Fibromyalgia Based on Pain Neuroscience Education, Exercise Therapy, Psychological Support, and Nature Exposure (NAT-FM): Study Protocol of a Randomized Controlled Trial.

PMID: 31963773
Journal: International Journal of Environmental Research and Public Health
Year: 2020
Reference: Int J Environ Res Public Health. 2020 Jan 19;17(2). pii: ijerph17020634. doi: 10.3390/ijerph17020634.
Impact factor: 2.849
Publication type: Paper in international publication
Authors: Serrat, Mayte, Sanabria-Mazo, Juan P, Garcia-Troiteiro, Elna, Fontcuberta, Anna, Mateo-Canedo, Corel, Almirall, Miriam, Feliu-Soler, Albert, Mendez-Ulrich, Jorge Luis, Sanz, Antoni, Luciano, Juan V et al.
DOI: 10.3390/ijerph17020634

Efficacy of a Multicomponent Intervention for Fibromyalgia Based on Pain Neuroscience Education, Exercise Therapy, Psychological Support, and Nature Exposure (NAT-FM): Study Protocol of a Randomized Controlled Trial.

PMID: 31963773
Journal: International Journal of Environmental Research and Public Health
Year: 2020
Reference: Int J Environ Res Public Health. 2020 Jan 19;17(2). pii: ijerph17020634. doi: 10.3390/ijerph17020634.
Impact factor:
Publication type: Paper in international publication
Authors: Almirall, Miriam; Feliu-Soler, Albert; Fontcuberta, Anna; Garcia-Troiteiro, Elna; Luciano, Juan V; Mateo-Canedo, Corel; Mendez-Ulrich, Jorge Luis; Sanabria-Mazo, Juan P; Sanz, Antoni; Serrat, Mayte et al.
DOI: 10.3390/ijerph17020634

Publications

Publications searcher

Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane.

Effet de l'Evobrutinib, inhibiteur de la tyrosine kinase de Bruton, sur les taux de cellules immunitaires et d'immunoglobulines sur 48 semaines dans le cadre d'une etude de phase 2 sur la sclerose en plaques recurrente.

Effet de l'Evobrutinib, inhibiteur de la tyrosine kinase de Bruton, sur les taux de cellules immunitaires et d'immunoglobulines sur 48 semaines dans le cadre d'une etude de phase 2 sur la sclerose en plaques recurrente.

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.

Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.

Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.

Efficacy of a Multicomponent Intervention for Fibromyalgia Based on Pain Neuroscience Education, Exercise Therapy, Psychological Support, and Nature Exposure (NAT-FM): Study Protocol of a Randomized Controlled Trial.

Efficacy of a Multicomponent Intervention for Fibromyalgia Based on Pain Neuroscience Education, Exercise Therapy, Psychological Support, and Nature Exposure (NAT-FM): Study Protocol of a Randomized Controlled Trial.

Patronage:

Collaborating:

Accreditations: